替比夫定单用及其联合阿德福韦酯治疗高病毒载量慢性乙型肝炎初治患者的临床观察  

Efficacy and safety of telbivudine alone and combined with adefovir for the treatment of nucleos（t）ide-naive chronic hepatitis B in patients with high-level hepatitis B virus load

作　　者：姚娜[1] 汪春付[1] 于卓然[1] 赵柯[1] 康文[1] 刘青[1] 党便利 孙永涛[1] 

机构地区：[1]第四军医大学附属唐都医院,西安710038

出　　处：《中华肝脏病杂志》2015年第4期250-253,共4页Chinese Journal of Hepatology

摘　　要：目的比较采用替比夫定（LdT）单药及其联合阿德福韦酯（ADV）治疗HBeAg阳性，高病毒载量的慢性乙型肝炎初治患者的疗效与安全性，分析服药依从性与治疗结局的关系。方法选择HBeAg阳性、HBV DNA≥107拷贝／ml的慢性乙型肝炎初治患者123例进行回顾性研究。联合组53例采用LdT 600mg／d联合ADV 10mg／d治疗，70例单药组采用LdT 600mg／d治疗。观察两组在治疗第12、24、48周时的HBV DNA阴转率、丙氨酸转氨酶（ALT）的复常率、血清HBeAg转换率、耐药和不良反应发生率，同时对患者进行依从性调查，分析与病毒耐药的相关性。符合正态分布的资料采用t检验；计量资料采用X2检验或Fisher精确检验。结果联合组在治疗第12、24、48周时血清HBV DNA低于检测下限者分别为62．3％（33／53）、88．％（47／53）、94．3％（50／53），其中治疗第12周和第24周与单药组相比较，差异有统计学意义（P〈0．05）；两组ALIT复常率在治疗第12周时分别为94．3％和77．1％，差异有统计学意义（P〈0．05）；联合组HBeAg血清转换率在第48周时为39．6％，与单药组相比较，差异有统计学意义（P〈0．05）。联合治疗组与单药治疗组在48周时的总耐药率分别为3-8％和11．4％，其中依从性差的比例占53．3％（8／15），依从性与治疗结局有关（P〈0．05）。治疗过程中两组均未观察到明显不良反应。结论对HBeAg阳性且病毒载量高的慢性乙型肝炎患者，起始启动LdT联合ADV治疗比LdT单药起效更快，且耐药率更低。患者的依从性是影响治疗结局的关键因素。Objective To compare the efficacy of telbivudine monotherapy and telbivudine combination therapy with adefovir in patients with nucleos（t）ide-naive chronic hepatitis B, high-level hepatitis B virus （HBV） load and hepatitis B e antigen （HBeAg）-positivity, and to explore the relationship between treatment regimen adherence and treatment outcomes. Methods A retrospective study was performed with 123 HBeAg-positive, high-level viral load （HBV DNA ~〉 107copies/ml）, nucleos（t）ide-naive chronic hepatitis B patients. Fifty-three of the patients received combination therapy with telbivudine and adefovir dipivoxil, while 70 patients received ＇the telbivudine monotherapy. All patients were tested for rates of conversion to HBV DNA-negative status, alanine aminotransferase （ALT） normalization, HBeAg seroconversion, drug resistance, and side effects at treatment weeks 12, 24, and 48. Treatment regimen adherence was assessed through self-reporting, and interviews were used to explore the relationships to treatment outcomes. The chi- square test, t test and Fisher＇s exact test were used for statistical analyses. Results The rates of HBV DNA negative conversion in the combination group at treatment weeks 12, 24 and 48 were 62.3% （33/53）, 88.7% （47/53） and 94.3% （50/53） and were significantly different from those in the monotherapy group at weeks 12 and 24. The rates of ALT normalization were significantly different between the two groups at treatment week 12 （94.3% vs. 77.1%）. The rate of HBeAg seroconversion in the combination group at treatment week 48 was 39.6%, and significantly different than that of the monotherapy group. The rates of drug-resistance in the combination and monotherapy groups at treatment week 48 were 3.8% and 11.4%, and the proportion of non-adherence to the treatment regimen was 53.3%, which significantly affected treatment outcome. No side effects occurred in either treatment group. Conclusion Telbivudine combination treatment with adefovir was more effective

关 键 词：肝炎 乙型 慢性 治疗 联合治疗 替比夫定 阿德福韦酯 

分 类 号：R512.62[医药卫生—内科学]